Obesity Drug Price War Begins
The GLP-1 drug market is shifting as supply shortages ease — pharma giants Eli Lilly and Novo Nordisk have started reducing costs and expanding affordability programs. It's a classic market access play to build brand loyalty, but Lilly is simultaneously maintaining premium pricing on its newest drugs, signaling a dual strategy of capturing volume and value.
The escalating price war in the GLP-1 market for obesity has seen Novo Nordisk announce plans to slash the U.S. list prices of its key drugs, Ozempic and Wegovy, by up to 50% starting January 1, 2027. This move will bring the monthly cost of both medications down to $675, a direct challenge to Eli Lilly's competing drugs. Analysts see this as a strategic response to pressure from Lilly's Zepbound and a broader effort to improve affordability for patients in high-deductible health plans. In the immediate term, both companies are leveraging savings programs to expand access. Eli Lilly's Zepbound Savings Card can lower the monthly cost to as little as $25 for patients with commercial insurance that covers the drug. For those with commercial insurance that doesn't cover Zepbound, the card can still reduce the monthly price by up to $563. Similarly, Novo Nordisk has updated its Wegovy savings program, allowing eligible cash-paying patients to access the drug for $499 per month. To address the widespread shortages that have plagued the GLP-1 market, both pharmaceutical giants are making multi-billion dollar investments in manufacturing. Eli Lilly has committed to a $5.3 billion expansion of its Indiana manufacturing site and a total of $27 billion in its U.S. manufacturing footprint. Not to be outdone, Novo Nordisk is investing $4.1 billion in a new plant in North Carolina and its parent company, Novo Holdings, is acquiring three fill-finish sites through a $16.5 billion buyout of Catalent. The competitive landscape is further complicated by the arrival of generics. In August 2025, Teva Pharmaceuticals received FDA approval for the first generic version of liraglutide (Saxenda), a GLP-1 drug for weight loss. While liraglutide is an older, less effective GLP-1, the introduction of a generic option is expected to increase patient access and put downward pressure on the prices of branded drugs. The next frontier in the obesity drug market is the development of more convenient and effective treatments. The race for a successful oral GLP-1 pill is a key focus, with Novo Nordisk gaining FDA approval for a once-daily 25-milligram oral version of semaglutide (Wegovy) in December 2025. Eli Lilly is also advancing its oral candidate, orforglipron. Pfizer, however, recently discontinued the development of its oral GLP-1 candidate, danuglipron, due to safety concerns. Beyond the duopoly, a new wave of competitors is emerging with novel approaches. Amgen's MariTide, a dual GLP-1/GIP receptor antagonist, is in Phase 3 trials and is being explored for monthly dosing. Viking Therapeutics is fast-tracking its dual GLP-1/GIP agonist, VK2735, into Phase 3 trials and is also investigating a monthly dosing schedule. These developments signal a future of increased competition and a wider range of treatment options for obesity.
